See more : US-Dadi Fertilizer Industry International, Inc. (USDF) Income Statement Analysis – Financial Results
Complete financial analysis of Bioasis Technologies Inc. (BTI.V) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bioasis Technologies Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Quaser Machine Tools, Inc. (4563.TWO) Income Statement Analysis – Financial Results
- Sangetsu Corporation (8130.T) Income Statement Analysis – Financial Results
- Man Group Limited (EMG.L) Income Statement Analysis – Financial Results
- Sun Corporation (6736.T) Income Statement Analysis – Financial Results
- AFC Gamma, Inc. (AFCG) Income Statement Analysis – Financial Results
Bioasis Technologies Inc. (BTI.V)
About Bioasis Technologies Inc.
Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). It has research collaborations with Aposense Limited to focus on the delivery of siRNA therapeutics for CNS disorders; Oxyrane UK Ltd. to focus on combining xB3 technology and Oxyrane's OxyCAT platform to deliver an undisclosed enhanced enzyme replacement therapy into the brain; and Janssen Biotech, Inc. to research, develop, and commercialize novel products based on Bioasis' xB3 platform. The company also has a research collaboration and license agreement with Neuramedy Co Ltd. to research, develop, and commercialize an xB3TM version of its antibody, Tomaralimab. Bioasis Technologies Inc. was incorporated in 2006 and is headquartered in New Haven, Connecticut.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 37.73K | 4.08M | 606.38K | 1.42M | 589.84K | 512.97K | 369.12K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 54.92K | 0.00 | 0.00 | 10.44K | 467.87K | 429.85K | 423.80K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -17.19K | 4.08M | 606.38K | 1.41M | 121.98K | 83.12K | -54.68K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | -45.57% | 100.00% | 100.00% | 99.27% | 20.68% | 16.20% | -14.81% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 1.23M | 1.24M | 2.03M | 1.95M | 946.81K | 783.78K | 841.05K | 1.35M | 2.00M | 1.92M | 1.11M | 958.24K | 619.17K | 148.58K | 0.00 | 0.00 |
| General & Administrative | 0.00 | 2.41M | 2.46M | 3.17M | 4.31M | 4.45M | 2.29M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.22M | 1.50M | 924.72K | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -27.60K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 2.41M | 2.46M | 3.17M | 4.31M | 4.45M | 2.29M | 1.67M | 1.49M | 1.64M | 3.07M | 1.83M | 1.20M | 1.50M | 924.72K | 143.21K | 0.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.19K | -4.83K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 0.00 | 3.63M | 3.70M | 5.21M | 6.27M | 5.40M | 3.07M | 2.51M | 2.84M | 3.64M | 4.99M | 2.94M | 2.16M | 2.22M | 1.17M | 143.21K | 5.00K |
| Cost & Expenses | 0.00 | 3.63M | 3.70M | 5.21M | 6.28M | 5.87M | 3.50M | 2.93M | 2.84M | 3.64M | 4.99M | 2.94M | 2.16M | 2.22M | 1.17M | 143.21K | 5.00K |
| Interest Income | 0.00 | 0.00 | 0.00 | 1.78K | 11.35K | 5.49K | 7.73K | 19.48K | 30.84K | 26.16K | 4.34K | 7.99K | 6.54K | 22.55K | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 654.21K | 35.85K | 46.90K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 54.92K | 60.49K | 70.77K | 71.99K | 58.88K | 50.47K | 51.32K | 51.32K | 51.47K | 52.82K | 120.67K | 116.88K | 108.56K | 107.92K | 99.03K | 0.00 | 0.00 |
| EBITDA | 0.00 | -3.54M | -22.82K | -4.53M | -4.79M | -5.22M | -2.94M | -2.51M | -2.77M | -3.58M | -4.88M | -2.82M | -2.05M | -2.12M | -1.07M | -143.21K | -5.00K |
| EBITDA Ratio | 0.00% | -12,810.50% | -0.56% | -844.86% | -433.69% | -877.58% | -570.18% | -676.22% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 0.00 | -4.89M | -83.31K | -5.19M | -6.24M | -5.24M | -2.99M | -2.56M | -2.84M | -3.64M | -4.99M | -2.94M | -2.16M | -2.22M | -1.17M | -143.21K | -5.00K |
| Operating Income Ratio | 0.00% | -12,956.07% | -2.04% | -856.53% | -438.75% | -887.56% | -582.07% | -694.62% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 0.00 | 636.69K | 781.72K | 545.27K | 1.38M | -30.69K | -4.98K | -8.90K | 4.02K | 27.84K | 31.63K | 2.15K | -4.83K | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | 0.00 | -2.96M | 698.41K | -4.06M | -3.47M | -5.31M | -2.99M | -2.57M | -2.84M | -3.61M | -4.96M | -2.94M | -2.16M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | -7,846.50% | 17.13% | -668.95% | -244.26% | -899.89% | -583.04% | -697.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -636.69K | -318.33K | -545.27K | -1.38M | 30.69K | 4.98K | 8.90K | -4.02K | -27.84K | -31.63K | -2.15K | -7.99K | -6.54K | -22.55K | 131.13K | 5.00K |
| Net Income | 0.00 | -2.96M | 698.41K | -4.06M | -3.47M | -5.31M | -2.99M | -2.57M | -2.84M | -3.61M | -4.96M | -2.94M | -2.15M | -2.22M | -1.15M | -131.13K | -5.00K |
| Net Income Ratio | 0.00% | -7,846.50% | 17.13% | -668.95% | -244.26% | -899.89% | -583.04% | -697.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.00 | -0.04 | 0.01 | -0.07 | -0.06 | -0.10 | -0.07 | -0.06 | -0.07 | -0.09 | -0.13 | -0.09 | -0.08 | -0.08 | -0.07 | -0.04 | -0.22 |
| EPS Diluted | 0.00 | -0.04 | 0.01 | -0.07 | -0.06 | -0.10 | -0.07 | -0.06 | -0.07 | -0.09 | -0.13 | -0.09 | -0.08 | -0.08 | -0.07 | -0.04 | -0.22 |
| Weighted Avg Shares Out | 0.00 | 72.17M | 68.12M | 62.27M | 56.68M | 50.90M | 45.42M | 44.44M | 42.98M | 40.84M | 37.99M | 32.57M | 28.55M | 26.73M | 17.18M | 2.99M | 23.17K |
| Weighted Avg Shares Out (Dil) | 0.00 | 72.17M | 68.12M | 62.27M | 56.68M | 50.90M | 45.42M | 44.44M | 42.98M | 40.84M | 37.99M | 32.57M | 28.55M | 26.73M | 17.18M | 2.99M | 23.17K |
Bioasis and Chiesi Group to Host Webcast on July 16, 2020
Source: https://incomestatements.info
Category: Stock Reports